Copper Chelation Delays the Onset of Prion Disease

Einar M. Sigurdsson, David R. Brown, Muhammad A. Alim, Henrieta Scholtzova, Richard Carp, Harry C. Meeker, Frances Prelli, Blas Frangione

Journal of Biological Chemistry · 2003 · 185 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

The prion protein (PrP) binds copper and under some conditions copper can facilitate its folding into a more protease resistant form. Hence, copper levels may influence the infectivity of the scrapie form of prion protein (PrPSc). To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, d-(–)-penicillamine (d-PEN), starting immediately following intraperitoneal scrapie inoculation. d-PEN delayed the onset of prion disease in the mice by about 11 days (p = 0.002), and reduced copper levels in brain by 29% (p < 0.01) and in blood by 22% (p = 0.03) compared with control animals. Levels of other metals were not significantly altered in the blood or brain. Modest correlation was observed between incubation period and levels of copper in brain (p = 0.08) or blood (p = 0.04), indicating that copper levels are only one of many factors that influence the rate of progression of prion disease. In vitro, copper dose-dependently enhanced the proteinase K resistance of the prion protein, and this effect was counteracted in a dose-dependent manner by co-incubation with d-PEN. Overall, these findings indicate that copper levels can influence the conformational state of PrP, thereby enhancing its infectivity, and this effect can be attenuated by chelatorbased therapy. The prion protein (PrP) binds copper and under some conditions copper can facilitate its folding into a more protease resistant form. Hence, copper levels may influence the infectivity of the scrapie form of prion protein (PrPSc). To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, d-(–)-penicillamine (d-PEN), starting immediately following intraperitoneal scrapie inoculation. d-PEN delayed the onset of prion disease in the mice by about 11 days (p = 0.002), and reduced copper levels in brain by 29% (p < 0.01) and in blood by 22% (p = 0.03) compared with control animals. Levels of other metals were not significantly altered in the blood or brain. Modest correlation was observed between incubation period and levels of copper in brain (p = 0.08) or blood (p = 0.04), indicating that copper levels are only one of many factors that influence the rate of progression of prion disease. In vitro, copper dose-dependently enhanced the proteinase K resistance of the prion protein, and this effect was counteracted in a dose-dependent manner by co-incubation with d-PEN. Overall, these findings indicate that copper levels can influence the conformational state of PrP, thereby enhancing its infectivity, and this effect can be attenuated by chelatorbased therapy. Transition metal ions, such as copper, manganese, iron, and zinc, are thought to be involved in the pathological events of various neurodegenerative diseases (1Bush A.I. Trends Neurosci. 2003; 26: 207-214Abstract Full Text Full Text PDF PubMed Scopus (1130) Google Scholar). Although these ions are unlikely to have a causative effect, disease-induced alterations in their homeostasis may contribute to the progression of the pathology, possibly by altering the conformation of proteins and/or by enhancing their aggregation. Additionally, these ions can promote oxidation and generation of free radicals. Although copper has been implicated in the pathogenesis of prion disease, it is unclear if this ion may promote or attenuate disease progression. Prior to the discovery of the prion protein, some similarities were observed in the neuropathology associated with the toxicity of the copper chelator cuprizone and the neuropathology of scrapie (2Kimberlin R.H. Millson G.C. Bountiff L. Collis S.C. J. Comp. Pathol. 1974; 84: 263-270Crossref PubMed Scopus (31) Google Scholar, 3Pattison I.H. Jebbett J.N. Nature. 1971; 230: 115-117Crossref PubMed Scopus (50) Google Scholar). However, copper supplementation does not prevent the development of cuprizone-induced spongy degeneration, indicating that these toxic effects may not be mediated by copper chelation. Conversely, one of Creutzfeldt's original patients later turned out to have had Wilson's disease (4Brown D.R. Biochem. Soc. Trans. 2002; 30: 742-745Crossref PubMed Scopus (25) Google Scholar), a copper storage disorder characterized by accumulation of copper in various organs (5Subramanian I. Vanek Z.F. Bronstein J.M. Curr. Neurol. Neurosci. Rep. 2002; 2: 317-323Crossref PubMed Scopus (27) Google Scholar). A biochemical link between the prion protein and copper was established when copper affinity chromatography allowed purification of the protein (6Pan K.M. Stahl N. Prusiner S.B. Protein Sci. 1992; 1: 1343-1352Crossref PubMed Scopus (174) Google Scholar), and copper was subsequently shown to alter the secondary structure of prion peptides (7Hornshaw M.P. McDermott J.R. Candy J.M. Lakey J.H. Biochem. Biophys. Res. Commun. 1995; 214: 993-999Crossref PubMed Scopus (295) Google Scholar, 8Qin K. Yang D.S. Yang Y. Chishti M.A. Meng L.J. Kretzschmar H.A. Yip C.M. Fraser P.E. Westaway D. J. Biol. Chem. 2000; 275: 19121-19131Abstract Full Text Full Text PDF PubMed Scopus (153) Google Scholar). Further characterization has indicated that the octapeptide repeat region of the prion protein binds several copper ions at least in the micromolar range (9Brown D.R. Qin K. Herms J.W. Madlung A. Manson J. Strome R. Fraser P.E. Kruck T. von Bohlen A. Schulz-Schaeffer W. Giese A. Westaway D. Kretzschmar H. Nature. 1997; 390: 684-687Crossref PubMed Scopus (37) Google Scholar, 10Viles J.H. Cohen F.E. Prusiner S.B. Goodin D.B. Wright P.E. Dyson H.J. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 2042-2047Crossref PubMed Scopus (510) Google Scholar, 11Miura T. Hori-I A. Mototani H. Takeuchi H. Biochemistry. 1999; 38: 11560-11569Crossref PubMed Scopus (248) Google Scholar, 12Whittal R.M. Ball H.L. Cohen F.E. Burlingame A.L. Prusiner S.B. Baldwin M.A. Protein Sci. 2000; 9: 332-343Crossref PubMed Scopus (227) Google Scholar, 13Kramer M.L. Kratzin H.D. Schmidt B. Romer A. Windl O. Liemann S. Hornemann S. Kretzschmar H. J. Biol. Chem. 2001; 276: 16711-16719Abstract Full Text Full Text PDF PubMed Scopus (241) Google Scholar) and likely with a femtomolar affinity (14Jackson G.S. Murray I. Hosszu L.L. Gibbs N. Waltho J.P. Clarke A.R. Collinge J. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 8531-8535Crossref PubMed Scopus (457) Google Scholar). The biological significance of this interaction is not clear but the normal cellular form of the prion protein, PrPC, 1The abbreviations used are: PrPCcellular form of PrPPrPprion proteinPrPScscrapie form of PrPd-PENd-(–)-penicillaminePBSphosphate-buffered salinePKproteinase KANOVAanalysis of variance. may be involved in copper uptake into cells (15Brown D.R. J. Neurosci. Res. 1999; 58: 717-725Crossref PubMed Scopus (104) Google Scholar, 16Pauly P.C. Harris D.A. J. Biol. Chem. 1998; 273: 33107-33110Abstract Full Text Full Text PDF PubMed Scopus (542) Google Scholar), and PrPC has a copper-dependent superoxide dismutase activity (17Brown D.R. Wong B.S. Hafiz F. Clive C. Haswell S.J. Jones I.M. Biochem. J. 1999; 344: 1-5Crossref PubMed Scopus (495) Google Scholar). cellular form of PrP prion protein scrapie form of PrP d-(–)-penicillamine phosphate-buffered saline proteinase K analysis of variance. To the best of our knowledge, only one study has determined whether there is an association between copper and prion infectivity (18McKenzie D. Bartz J. Mirwald J. Olander D. Marsh R. Aiken J. J. Biol. Chem. 1998; 273: 25545-25547Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar). Those findings indicate that copper enhances reversibility of scrapie inactivation in vitro by facilitating refolding of denatured PrPSc into a protease-resistant and infectious form. Hence, increased copper may enhance the infectivity of PrPSc. To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, d-penicillamine (d-PEN). This compound is a derivative of penicillin and is the chelator most commonly used to treat Wilson's disease. Additional uses are in treating cystinuria, heavy metal poisoning, rheumatoid arthritis, and certain collagen disorders. We report here that d-PEN delays the onset of prion disease in mice, indicating that copper promotes prionosis. Animals—Two- to three-month-old CD-1 mice received 100 mg/kg of d-PEN (Sigma) dissolved in distilled water and delivered as a 100-μl intraperitoneal dose. The solution was prepared immediately before use to avoid disulphide formation. Control mice received water injections. The dose of d-PEN chosen for this experiment was based on a previous report showing that mice force-fed with 100 mg/kg body weight of d-PEN had a delay in the onset of amyotrophic lateral sclerosis (19Hottinger A.F. Fine E.G. Gurney M.E. Zurn A.D. Aebischer P. Eur. J. Neurosci. 1997; 9: 1548-1551Crossref PubMed Scopus (161) Google Scholar). Mice fed 0.5 g of d-PEN per kg of diet for up to 48 weeks have been reported not to have any abnormalities (20Takeda T. Yao C.S. Irino M. Tashiro S.I. Yasuhira K. Toxicol. Appl. Pharmacol. 1980; 55: 324-333Crossref PubMed Scopus (8) Google Scholar). A mouse consumes on average around 150 g of chow per month, which corresponds to a dosage of about 75 mg of drug ingested per month. The injected dose used in the current study is equivalent to 43 mg of d-PEN per month for a mouse weighing 20 g. The mice had access to food and water ad libitum and were fed a standard diet, Purina No. 5015. The first injection was delivered immediately following scrapie inoculation, and subsequent injections were performed daily, 5 days a week. The mice (n = 10 per group) were inoculated intraperitoneally with a brain homogenate of the mouse-adapted scrapie strain 139A at a 10-fold and a 1000-fold dilution. The mice were monitored for clinical signs of scrapie, starting a few weeks before the expected onset of symptoms. The activity level and competency of the mice were assessed on an apparatus that contained a series of parallel bars (3 mm in diameter) placed 7 mm apart, as per an established protocol (21Carp R.I. Callahan S.M. Sersen E.A. Moretz R.C. Intervirology. 1984; 21: 61-69Crossref PubMed Scopus (64) Google Scholar, 22Aucouturier P. Geissmann F. Damotte D. Saborio G.P. Meeker H.C. Kascsak R. Kascsak R. Carp R.I. Wisniewski T. J. Clin. Invest. 2001; 108: 703-708Crossref PubMed Scopus (160) Google Scholar, 23Sigurdsson E.M. Brown D.R. Daniels M. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Am. J. Pathol. 2002; 161: 13-17Abstract Full Text Full Text PDF PubMed Scopus (172) Google Scholar, 24Sigurdsson E.M. Sy M.S. Li R. Scholtzova H. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Neurosci. Lett. 2003; 336: 185-187Crossref PubMed Scopus (98) Google Scholar). Mice with signs of prion disease have reduced activity and/or diminished ability to traverse the bars. The mice were euthanized when they rated as positive 3 weeks in a row by two observers blinded to the experimental status of the animals. This clinical end point is known to be associated with extensive scrapie pathology in the central nervous system of these mice (21Carp R.I. Callahan S.M. Sersen E.A. Moretz R.C. Intervirology. 1984; 21: 61-69Crossref PubMed Scopus (64) Google Scholar, 22Aucouturier P. Geissmann F. Damotte D. Saborio G.P. Meeker H.C. Kascsak R. Kascsak R. Carp R.I. Wisniewski T. J. Clin. Invest. 2001; 108: 703-708Crossref PubMed Scopus (160) Google Scholar, 23Sigurdsson E.M. Brown D.R. Daniels M. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Am. J. Pathol. 2002; 161: 13-17Abstract Full Text Full Text PDF PubMed Scopus (172) Google Scholar, 24Sigurdsson E.M. Sy M.S. Li R. Scholtzova H. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Neurosci. Lett. 2003; 336: 185-187Crossref PubMed Scopus (98) Google Scholar). Histology—At the clinical end point, the brains were removed from mice deeply anesthetized with ketamine/xylazine. The right hemisphere was immersion-fixed overnight in periodate-lysine-paraformaldehyde solution, and the left hemisphere was snap-frozen for measurements of copper levels. The periodate-lysine-paraformaldehyde solution-fixed brain hemisphere was transferred to 0.1 m sodium phosphate buffer containing 20% glycerol and 2% dimethyl sulfoxide and stored at 4 °C until sectioned. Coronal sections of 40 μm were cut, and a series of sections at 0.2-mm intervals were stained with cresyl violet and anti-PrP 78295 (courtesy of R. Kascsak, Institute for Basic Research in Developmental Disabilities, Staten Island, NY) (25Kascsak R.J. Fersko R. Pulgiano D. Rubenstein R. Carp R.I. Immunol. Invest. 1997; 26: 259-268Crossref PubMed Scopus (45) Google Scholar) to confirm the diagnosis of prion disease. Metal Analysis—Trace element content of brain was determined using inductively coupled plasma mass spectrometry as reported previously (26Thackray A.M. Knight R. Haswell S.J. Bujdoso R. Brown D.R. Biochem. J. 2002; 362: 253-258Crossref PubMed Scopus (176) Google Scholar, 27Wong B.S. Chen S.G. Colucci M. Xie Z. Pan T. Liu T. Li R. Gambetti P. Sy M.S. Brown D.R. J. Neurochem. 2001; 78: 1400-1408Crossref PubMed Scopus (184) Google Scholar). Briefly, all labware used was acid-leached overnight under pressure to reduce metal contaminants. Brain hemispheres were hydrolyzed in nitric acid (1 ml of SpA grade per 100-μl sample) at room temperature overnight. The samples were then sealed, to and to at least °C for 10 The hydrolyzed samples were to nitric acid before for metal were prepared from To the a standard solution was of was at least and the was with 2% nitric acid for between In from mice at the of with scrapie strain 139A were in various containing mm and a of protease from mice were used as The phosphate-buffered saline 10 mm 150 mm and 100 mm the homogenate was at and the was then with or 10 mm or and and 100 of d-PEN at for In incubation with copper or copper in a dose-dependent enhanced resistance of the prion protein to proteinase K and copper was used in all subsequent indicated that incubation of the samples for in in a of the brain biological in the or but at copper was only in or buffer was used for all subsequent and the are from samples in that of was transferred into a and with proteinase K at for Brain with 100 mm d-PEN as as samples copper and d-PEN were as the buffer containing (Sigma) was and the samples were for 5 and then were on a sodium containing were performed with the of that of the prion protein E.M. Sy M.S. Li R. Scholtzova H. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Neurosci. Lett. 2003; 336: 185-187Crossref PubMed Scopus (98) Google Scholar, R. Liu T. Wong B.S. Pan T. M. W. K. Gambetti P. Sy M.S. J. Biol. 2000; PubMed Scopus Google Scholar, B.S. Li R. J. S.C. Liu T. Pan T. Wisniewski T. Brown D.R. Sy Sci. 2003; PubMed Scopus Google Scholar). were with which binds to PrP E.M. Sy M.S. Li R. Scholtzova H. Kascsak R.J. Kascsak R. Carp R. Meeker H.C. Frangione B. Wisniewski T. Neurosci. Lett. 2003; 336: 185-187Crossref PubMed Scopus (98) Google Scholar, R. Liu T. Wong B.S. Pan T. M. W. K. Gambetti P. Sy M.S. J. Biol. 2000; PubMed Scopus Google Scholar, B.S. Li R. J. S.C. Liu T. Pan T. Wisniewski T. Brown D.R. Sy Sci. 2003; PubMed Scopus Google Scholar). The secondary was and the was with the was performed by the of a from compared with the of the from the of a control PrPSc brain copper a of were with and and or one vitro analysis of by the was determined by the correlation in copper levels in brain and reduced brain copper levels (p < by by = by and = by in the treated mice compared with control animals. levels in blood were in the treated mice (p = 0.03) by and = Brain and blood levels of manganese, iron, zinc, and were not altered not are as vitro, d-PEN resistance of the prion from mice were in and the samples were for at °C to A that copper dose-dependently promotes resistance of the prion of scrapie brain in and following in was and by with The and the whether was not or it is indicated whether the samples were with copper and its scrapie with and copper scrapie brain with copper content The in PrPC and with the the in as are of scrapie brain following incubation with copper at and The shown in are of PrPSc and are more in the samples with of copper, to of the copper resistance of the prion The of a was and the observed following of brain homogenate copper as not the of in the of the resistant (p = = 4 per The that received 5 and 10 mm copper significantly from the 0.1 mm = and this effect is by which by has effect on protein was performed in the as manner as in B. d-PEN by had effect on but dose-dependently copper resistance of the prion the of (p = = 3 per group) in the of the The was observed in the that received 10 mm copper compared with all the other = d-PEN delayed the onset of prion disease in the mice a effect (p = and a effect (p < but interaction between the two analysis a delay in disease onset in the the 1000-fold of the brain homogenate = 3 = = and a for a delay the the 10-fold = = = d-PEN reduced brain copper levels (p < by = and = in the treated mice compared with control Brain levels of manganese, iron, zinc, and were not altered not The copper levels we report in mice are to (26Thackray A.M. Knight R. Haswell S.J. Bujdoso R. Brown D.R. Biochem. J. 2002; 362: 253-258Crossref PubMed Scopus (176) Google Scholar, 27Wong B.S. Chen S.G. Colucci M. Xie Z. Pan T. Liu T. Li R. Gambetti P. Sy M.S. Brown D.R. J. Neurochem. 2001; 78: 1400-1408Crossref PubMed Scopus (184) Google Scholar). levels of metals a in the effect of d-PEN at this dose. levels were in the treated mice (p = by and = but the two not significantly from The levels of manganese, iron, zinc, and in the blood were not altered not To the that the effect of d-PEN was mediated its copper brain from mice were with copper with or d-PEN. with copper in a dose-dependent enhanced resistance of the prion protein to proteinase K (p = A and The increased resistance associated with the of copper was counteracted in a dose-dependent manner by co-incubation with d-PEN (p = A but effect of in resistance of PrP, and its by d-PEN was observed in control in which the brain homogenate was from mice not that copper may the conformation of PrPC and PrPSc. Overall, these findings the in effect of d-PEN in the onset of prion disease in the animals. To the of copper in the development of clinical of prion disease, we injected mice with the copper chelator d-PEN using a dose mg/kg body that has been shown to be toxic effects in mice (20Takeda T. Yao C.S. Irino M. Tashiro S.I. Yasuhira K. Toxicol. Appl. Pharmacol. 1980; 55: 324-333Crossref PubMed Scopus (8) Google Scholar). Although d-PEN may other ions at of a dose about we used in our study has been shown not to other metals M. Yasuhira K. T. Toxicol. Appl. Pharmacol. PubMed Scopus Google Scholar). our measurements of brain and plasma levels of copper, and other metal ions the of d-PEN for copper ions at the dose we The mice in our study that received the chelator clinical significantly later the control indicating that copper levels may delay disease progression. A in vitro study has shown that copper may enhance the of denatured PrPSc (18McKenzie D. Bartz J. Mirwald J. Olander D. Marsh R. Aiken J. J. Biol. Chem. 1998; 273: 25545-25547Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar), study has that the protease of PrPSc can be altered by copper and ions as as by metal A.F. S. G.S. Clarke A.R. Collinge J. Biol. 1999; 1: PubMed Scopus Google Scholar), that metal ions may be involved in certain of the prion protein and thereby facilitate its to the PrPSc form. of copper reduce PrPSc and/or its The effect of the chelator may be copper has effect Am. J. Clin. 1998; PubMed Scopus Google Scholar), and the system is involved in of C. F. I. R. M.A. A. Trans. R. Soc. Biol. Sci. 2001; PubMed Scopus Google Scholar). The correlation between incubation period and copper levels in brain (p = 0.08) and blood (p = that the progression of prion disease is by only one of which may be copper levels. Prior indicate that copper levels are reduced by up to in the brains of that to disease B.S. Brown D.R. Pan T. M. Liu T. Li R. Gambetti P. J. Rubenstein R. Sy M.S. J. Neurochem. 2001; PubMed Scopus Google Scholar). We have observed a in mice, in which brain copper levels are reduced at the onset of clinical the of copper is increased in the (26Thackray A.M. Knight R. Haswell S.J. Bujdoso R. Brown D.R. Biochem. J. 2002; 362: 253-258Crossref PubMed Scopus (176) Google Scholar, 27Wong B.S. Chen S.G. Colucci M. Xie Z. Pan T. Liu T. Li R. Gambetti P. Sy M.S. Brown D.R. J. Neurochem. 2001; 78: 1400-1408Crossref PubMed Scopus (184) Google Scholar). clinical blood copper levels are in these measurements in the previous are in a range our prion mice have been shown to have copper levels but of and in (9Brown D.R. Qin K. Herms J.W. Madlung A. Manson J. Strome R. Fraser P.E. Kruck T. von Bohlen A. Schulz-Schaeffer W. Giese A. Westaway D. Kretzschmar H. Nature. 1997; 390: 684-687Crossref PubMed Scopus (37) Google Scholar), brain copper content has been reported not to be by prion levels B. J.R. Harris D.A. J. Biol. Chem. 2000; 275: Full Text Full Text PDF PubMed Scopus Google Scholar). The findings of brain copper levels in patients and not on the of copper has on prion copper has been shown to with to PrPC to the scrapie PrPSc B.S. Chen S.G. Colucci M. Xie Z. Pan T. Liu T. Li R. Gambetti P. Sy M.S. Brown D.R. J. Neurochem. 2001; 78: 1400-1408Crossref PubMed Scopus (184) Google Scholar, Y. H. N. M. R. J. 2001; PubMed Scopus Google Scholar, W. A. A. P. J. M. A. S. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar), copper levels observed in the brains of patients and may enhanced of central nervous system copper in vitro that copper enhances resistance of PrPSc and PrPC and that this effect can be by d-PEN a of copper on the conformational state of of PrPSc and copper levels to be performed the of the disease to the of copper in progression of prion disease. Overall, our findings that therapy can the incubation of prion disease. determine whether with effects may prevent disease and the of this in therapy. the of for prion We Knight for with metal

References

32